Market revenue in 2023 | USD 1,087.9 million |
Market revenue in 2030 | USD 1,543.3 million |
Growth rate | 5.1% (CAGR from 2023 to 2030) |
Largest segment | Biopharmaceuticals |
Fastest growing segment | Biopharmaceuticals |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Biopharmaceuticals |
Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.73% in 2023. Horizon Databook has segmented the France rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
The France rheumatoid arthritis therapeutics market is witnessing significant advancements with the collaboration between Gilead Sciences, Inc. and EVOQ Therapeutics, Inc., announced in January 2023. This collaboration aims to leverage EVOQ's innovative Nano Disc technology.
This technology can potentially revolutionize the treatment landscape for autoimmune diseases by offering targeted and effective therapeutic solutions. Gilead and EVOQ's collaboration involves joint efforts in preclinical development, with Gilead having the option to exclusively license rights to EVOQ's Nano Disc technology for developing product candidates targeting RA and lupus indications.
Furthermore, Gilead will lead clinical development and commercialization, highlighting the company's commitment to advancing innovative treatments for autoimmune diseases in the French market. This collaboration signifies a strategic move toward personalized and targeted therapies, addressing the underlying causes of RA and lupus.
Horizon Databook provides a detailed overview of country-level data and insights on the France rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into France rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account